Synopsis
Synopsis
0
JDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Citrate, Norflex Orphenadrine
2. Citrate, Orphenadrine
3. Disipal
4. Hydrochloride, Orphenadrine
5. Lysantin
6. Mefenamine
7. Mefenamine, Sodium
8. Mephenamine
9. Methyldiphenylhydramine
10. Norflex
11. Norflex Orphenadrine Citrate
12. Orphenadrine
13. Orphenadrine Citrate, Norflex
14. Orphenadrine Hydrochloride
15. Sodium Mefenamine
1. 4682-36-4
2. Norflex
3. Banflex
4. Orphenadrine Dihydrogen Citrate
5. Flexon
6. Orphenadrine (citrate)
7. Flexoject
8. X-otag
9. Orphenadrine Citrate Salt
10. 2-hydroxypropane-1,2,3-tricarboxylic Acid; Dimethyl({2-[(2-methylphenyl)(phenyl)methoxy]ethyl})amine
11. 4596-23-0
12. Nsc-757238
13. Orphenadrine Citrate [usp]
14. N,n-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine;2-hydroxypropane-1,2,3-tricarboxylic Acid
15. Orphenadrine Citrate (norflex)
16. Chebi:7790
17. X0a40n8i4s
18. N,n-dimethyl-2-(phenyl(o-tolyl)methoxy)ethanamine 2-hydroxypropane-1,2,3-tricarboxylate
19. Ncgc00094745-01
20. Plenactol
21. Euflex
22. Flexor
23. Tega-flex
24. Orphenadrine Citrate (usp)
25. Dsstox_cid_24678
26. Dsstox_rid_80390
27. Dsstox_gsid_44678
28. Norflex (pharmaceutical)
29. Orphenadrinecitrate
30. N,n-dimethyl-2-(phenyl(o-tolyl)methoxy)ethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate
31. Cas-4682-36-4
32. Einecs 225-137-5
33. Unii-x0a40n8i4s
34. Norflex (tn)
35. Orphenadine Citrate
36. N,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate (1:1)
37. Ethanamine, N,n-dimethyl-2-((2-methylphenyl)phenylmethoxy)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
38. Mls000069549
39. Schembl119470
40. Spectrum1500447
41. Chembl1200395
42. Dtxsid8044678
43. Hms502k15
44. Hy-b0369a
45. Orphenadrine Citrate [mi]
46. Hms1920d10
47. Hms2091l10
48. Hms2231j06
49. Hms3259m21
50. Hms3370m12
51. Hms3651a10
52. Hms3884m22
53. Pharmakon1600-01500447
54. Citric Acid; N,n-dimethyl-2-[o-tolyl(phenyl)methoxy]ethanamine
55. O-methyldiphenhydramine Citrate Salt
56. Orphenadrine Citrate [vandf]
57. Tox21_111323
58. Tox21_113543
59. Tox21_301079
60. Ccg-40242
61. Nsc757238
62. Orphenadrine Citrate [mart.]
63. Orphenadrine Citrate [who-dd]
64. Akos008132385
65. Tox21_111323_1
66. Nc00525
67. Nsc 757238
68. (+-)-n,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate (1:1)
69. Ethylamine, N,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)-, Citrate (1:1)
70. Ncgc00015771-13
71. Ncgc00094745-02
72. Ncgc00094745-03
73. Ncgc00254980-01
74. As-74807
75. Ethanamine, N,n-dimethyl-2-((2-methylphenyl)phenylmethoxy)-, (+-)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
76. Orphenadrine Citrate [ep Impurity]
77. Orphenadrine Citrate [orange Book]
78. Smr000058817
79. Orphenadrine Citrate [ep Monograph]
80. Orphenadrine Citrate [usp Monograph]
81. Ft-0655842
82. Ft-0673305
83. S2054
84. Sw102176-4
85. En300-53019
86. Norgesic Component Orphenadrine Citrate
87. C75247
88. D00774
89. Invagesic Component Orphenadrine Citrate
90. Orphenadrine Citrate Component Of Norgesic
91. Orphengesic Component Orphenadrine Citrate
92. A826945
93. Orphenadrine Citrate Component Of Invagesic
94. Orphenadrine Citrate Component Of Orphengesic
95. Sr-01000002975-5
96. Invagesic Forte Component Orphenadrine Citrate
97. Orphengesic Forte Component Orphenadrine Citrate
98. Q27107584
99. Orphenadrine Citrate Component Of Invagesic Forte
100. Orphenadrine Citrate Component Of Orphengesic Forte
101. Beta-dimethylaminoethyl 2-methylbenzhydryl Ether Citrate Salt
102. N,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate
103. (+-)-n,n-dimethyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine Citrate
104. (+/-)-n,n-dimethyl-2-((o-methyl-.alpha.-phenylbenzyl)oxy)ethylamine Citrate (1:1)
105. Ethanamine, N,n-dimethyl-2-((2-methylphenyl)phenylmethoxy)-, (+/-)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
106. Ethanamine, N,n-dimethyl-2-[(2-methylphenyl)phenylmethoxy]-,2-hydroxy-1,2,3-propanetricarboxylate (1:1)
107. N,n-dimethyl-2-[(2-methylphenyl)(phenyl)methoxy]ethanamine 2-hydroxypropane-1,2,3-tricarboxylate
| Molecular Weight | 461.5 g/mol |
|---|---|
| Molecular Formula | C24H31NO8 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 11 |
| Exact Mass | 461.20496695 g/mol |
| Monoisotopic Mass | 461.20496695 g/mol |
| Topological Polar Surface Area | 145 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 488 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Norflex |
| PubMed Health | Orphenadrine |
| Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
| Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2- methylbenzhydryl ether citrate). It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly solubl... |
| Active Ingredient | Orphenadrine citrate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 30mg/ml |
| Market Status | Prescription |
| Company | Medicis |
| 2 of 4 | |
|---|---|
| Drug Name | Orphenadrine citrate |
| PubMed Health | Orphenadrine Citrate/Aspirin/Caffeine (By mouth) |
| Drug Classes | Skeletal Muscle Relaxant, Centrally Acting/Salicylate, Aspirin Combination |
| Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine. It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. The chemical name of orphenadrine citrate i... |
| Active Ingredient | Orphenadrine citrate |
| Dosage Form | Tablet, extended release; Injectable |
| Route | Injection; Oral |
| Strength | 30mg/ml; 100mg |
| Market Status | Prescription |
| Company | Impax Pharms; Tedor Pharma; Sandoz; Invagen Pharms; Watson Labs; Gavis Pharms; Sagent Pharms; Eurohlth Intl; Akorn |
| 3 of 4 | |
|---|---|
| Drug Name | Norflex |
| PubMed Health | Orphenadrine |
| Drug Classes | Skeletal Muscle Relaxant, Centrally Acting |
| Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2- methylbenzhydryl ether citrate). It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly solubl... |
| Active Ingredient | Orphenadrine citrate |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 30mg/ml |
| Market Status | Prescription |
| Company | Medicis |
| 4 of 4 | |
|---|---|
| Drug Name | Orphenadrine citrate |
| PubMed Health | Orphenadrine Citrate/Aspirin/Caffeine (By mouth) |
| Drug Classes | Skeletal Muscle Relaxant, Centrally Acting/Salicylate, Aspirin Combination |
| Drug Label | Orphenadrine citrate is the citrate salt of orphenadrine. It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol. The chemical name of orphenadrine citrate i... |
| Active Ingredient | Orphenadrine citrate |
| Dosage Form | Tablet, extended release; Injectable |
| Route | Injection; Oral |
| Strength | 30mg/ml; 100mg |
| Market Status | Prescription |
| Company | Impax Pharms; Tedor Pharma; Sandoz; Invagen Pharms; Watson Labs; Gavis Pharms; Sagent Pharms; Eurohlth Intl; Akorn |
Cytochrome P-450 CYP2B6 Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2B6. (See all compounds classified as Cytochrome P-450 CYP2B6 Inhibitors.)
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Muscle Relaxants, Central
A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
M - Musculo-skeletal system
M03 - Muscle relaxants
M03B - Muscle relaxants, centrally acting agents
M03BC - Ethers, chemically close to antihistamines
M03BC01 - Orphenadrine (citrate)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7108
Submission : 1987-08-11
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-12-16
Pay. Date : 2013-07-05
DMF Number : 5722
Submission : 1985-02-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4811
Submission : 1983-01-21
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4457
Submission : 1982-02-08
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-11-13
Pay. Date : 2014-10-31
DMF Number : 14971
Submission : 2000-07-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2942
Submission : 1977-05-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38456
Submission : 2023-06-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33901
Submission : 2019-05-29
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7837
Submission : 1988-12-20
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Certificate Number : CEP 2022-094 - Rev 00
Status : Valid
Issue Date : 2024-05-21
Type : Chemical
Substance Number : 1759
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
Orphenadrine Citrate IP/USP/Ph.Eur/BP
Date of Issue : 2023-04-18
Valid Till : 2026-04-17
Written Confirmation Number : WC-0555
Address of the Firm : Plot No.: 165-182, APIIC Growth Center, Thumakunta, Anantapur-515211, Andhra Pra...
Orphenadrine Citrate BP/USP/Ph. Eur.
Date of Issue : 2022-10-14
Valid Till : 2025-07-28
Written Confirmation Number : WC-0445
Address of the Firm : Plot No. IP No. 27-29, Parts of Sy. Nos. 18, 273, 274 & 313, KIADB Industrial Ar...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]KDMF
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2020-10-13
Registration Number : 20201013-209-J-733
Manufacturer Name : RL Fine Chem Pvt Ltd
Manufacturer Address : Plot No. IP-27-29, KIADB Industrial Area, 1st Phase, Kudumalakunte Village, Gowribida...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
NDC Package Code : 51552-1353
Start Marketing Date : 2012-01-02
End Marketing Date : 2027-06-30
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 22568-1022
Start Marketing Date : 2021-06-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 38779-0452
Start Marketing Date : 2012-11-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 51927-0245
Start Marketing Date : 2022-09-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 51927-0006
Start Marketing Date : 2019-03-07
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 46016-0140
Start Marketing Date : 2003-09-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 71554-012
Start Marketing Date : 2019-04-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49452-4936
Start Marketing Date : 1997-10-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
Jai Radhe Sales is your partner for all your sourcing needs.
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
Harika Drugs has been providing a qualitative range of Bulk Drugs/ APIs since 1993.
About the Company : Our endeavours also lie in the import, and domestic sourcing of raw materials from reliable vendors of the market. We have an excellent infrastructure with world class cGMP facilit...
About the Company : Albemarle Corporation (NYSE: ALB), headquartered in Charlotte, NC, is a global specialty chemicals company with leading positions in lithium, bromine and refining catalysts. We pow...
About the Company : The division was established in 1981 as a Specialty Chemicals Division with a focus to manufacture specialty chemicals and pharmaceutical intermediates. In April 2006, the division...
About the Company : Public health is always an imperative that implies immense responsibility, not a mere re-adjustable option. As a company operating under world’s second largest industry of Pharma...
About the Company : Nortec Química stands as the largest manufacturer of Active Pharmaceutical Ingredients (IFAs) in Latin America, embarking on its mission to ensure the availability of quality medi...
About the Company : Procos S.p.A. is a wholly owned subsidiary of the Japanese company, CBC Co. Ltd Group, specializing in the development, scale-up and production of Active Pharmaceutical Ingredients...
About the Company : Established in 1984, R L Fine Chem Pvt. Ltd. is one of the fastest growing API companies, with a leadership position in several APIs such as antihistamines, antidepressants and mus...
About the Company : Established in 2002, Tecoland represents selected cGMP manufacturers with proven capabilities in organic synthesis, fermentation production as well as process and method developmen...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Granulation
Direct Compression
Controlled & Modified Release
Lubricants & Glidants
Disintegrants & Superdisintegrants
Thickeners and Stabilizers
Film Formers & Plasticizers
Taste Masking
Co-Processed Excipients
Chewable & Orodispersible Aids
Solubilizers
Parenteral
Rheology Modifiers
Empty Capsules
Emulsifying Agents
Vegetarian Capsules
API Stability Enhancers
Topical
Coloring Agents
Surfactant & Foaming Agents
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
31
PharmaCompass offers a list of Orphenadrine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Orphenadrine manufacturer or Orphenadrine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Orphenadrine manufacturer or Orphenadrine supplier.
PharmaCompass also assists you with knowing the Orphenadrine API Price utilized in the formulation of products. Orphenadrine API Price is not always fixed or binding as the Orphenadrine Price is obtained through a variety of data sources. The Orphenadrine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A NORGESIC FORTE-2 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of NORGESIC FORTE-2, including repackagers and relabelers. The FDA regulates NORGESIC FORTE-2 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. NORGESIC FORTE-2 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of NORGESIC FORTE-2 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A NORGESIC FORTE-2 supplier is an individual or a company that provides NORGESIC FORTE-2 active pharmaceutical ingredient (API) or NORGESIC FORTE-2 finished formulations upon request. The NORGESIC FORTE-2 suppliers may include NORGESIC FORTE-2 API manufacturers, exporters, distributors and traders.
click here to find a list of NORGESIC FORTE-2 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A NORGESIC FORTE-2 DMF (Drug Master File) is a document detailing the whole manufacturing process of NORGESIC FORTE-2 active pharmaceutical ingredient (API) in detail. Different forms of NORGESIC FORTE-2 DMFs exist exist since differing nations have different regulations, such as NORGESIC FORTE-2 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A NORGESIC FORTE-2 DMF submitted to regulatory agencies in the US is known as a USDMF. NORGESIC FORTE-2 USDMF includes data on NORGESIC FORTE-2's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The NORGESIC FORTE-2 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of NORGESIC FORTE-2 suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a NORGESIC FORTE-2 Drug Master File in Korea (NORGESIC FORTE-2 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of NORGESIC FORTE-2. The MFDS reviews the NORGESIC FORTE-2 KDMF as part of the drug registration process and uses the information provided in the NORGESIC FORTE-2 KDMF to evaluate the safety and efficacy of the drug.
After submitting a NORGESIC FORTE-2 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their NORGESIC FORTE-2 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of NORGESIC FORTE-2 suppliers with KDMF on PharmaCompass.
A NORGESIC FORTE-2 CEP of the European Pharmacopoeia monograph is often referred to as a NORGESIC FORTE-2 Certificate of Suitability (COS). The purpose of a NORGESIC FORTE-2 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of NORGESIC FORTE-2 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of NORGESIC FORTE-2 to their clients by showing that a NORGESIC FORTE-2 CEP has been issued for it. The manufacturer submits a NORGESIC FORTE-2 CEP (COS) as part of the market authorization procedure, and it takes on the role of a NORGESIC FORTE-2 CEP holder for the record. Additionally, the data presented in the NORGESIC FORTE-2 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the NORGESIC FORTE-2 DMF.
A NORGESIC FORTE-2 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. NORGESIC FORTE-2 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of NORGESIC FORTE-2 suppliers with CEP (COS) on PharmaCompass.
A NORGESIC FORTE-2 written confirmation (NORGESIC FORTE-2 WC) is an official document issued by a regulatory agency to a NORGESIC FORTE-2 manufacturer, verifying that the manufacturing facility of a NORGESIC FORTE-2 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting NORGESIC FORTE-2 APIs or NORGESIC FORTE-2 finished pharmaceutical products to another nation, regulatory agencies frequently require a NORGESIC FORTE-2 WC (written confirmation) as part of the regulatory process.
click here to find a list of NORGESIC FORTE-2 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing NORGESIC FORTE-2 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for NORGESIC FORTE-2 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture NORGESIC FORTE-2 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain NORGESIC FORTE-2 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a NORGESIC FORTE-2 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of NORGESIC FORTE-2 suppliers with NDC on PharmaCompass.
NORGESIC FORTE-2 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of NORGESIC FORTE-2 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right NORGESIC FORTE-2 GMP manufacturer or NORGESIC FORTE-2 GMP API supplier for your needs.
A NORGESIC FORTE-2 CoA (Certificate of Analysis) is a formal document that attests to NORGESIC FORTE-2's compliance with NORGESIC FORTE-2 specifications and serves as a tool for batch-level quality control.
NORGESIC FORTE-2 CoA mostly includes findings from lab analyses of a specific batch. For each NORGESIC FORTE-2 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
NORGESIC FORTE-2 may be tested according to a variety of international standards, such as European Pharmacopoeia (NORGESIC FORTE-2 EP), NORGESIC FORTE-2 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (NORGESIC FORTE-2 USP).
